Resource Summary Report

Generated by NIF on Sep 14, 2026

PE/Cyanine7 anti-human HLA-DR, DP, DQ

RRID:AB_2564279
Type: Antibody

Proper Citation

BioLegend Cat# 361708, RRID:AB_2564279

Antibody Information

URL: http://antibodyregistry.org/AB_2564279

Proper Citation: BioLegend Cat# 361708, RRID:AB_2564279

Target Antigen: HLA-DR DP DQ

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human HLA-DR, DP, DQ

Description: This monoclonal targets HLA-DR DP DQ

Target Organism: human

Clone ID: clone Tü39

Antibody ID: AB_2564279

Vendor: BioLegend

Catalog Number: 361708

Alternative Catalog Numbers: 361707

Record Creation Time: 20231110T035209+0000

Record Last Update: 20260830T024457+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human HLA-DR, DP, DQ.

No alerts have been found for PE/Cyanine7 anti-human HLA-DR, DP, DQ.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Wu Z, et al. (2025) Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell.

Zhou W, et al. (2024) Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. Cell reports, 43(2), 113797.

Pickles OJ, et al. (2023) MHC Class II is Induced by IFN? and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids. Cancer research communications, 3(8), 1501.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.